This site is intended for healthcare professionals
Drug news

Seattle Genetics files sBLA at FDA for Adcetris to treat CD30-expressing peripheral T-cell lymphoma (PTCL).

Read time: 1 mins
Last updated:6th Nov 2018
Published:6th Nov 2018
Source: Pharmawand

Seattle Genetics, Inc. announced that it has submitted a supplemental Biologics License Application (BLA) to the FDA based on data from the phase III ECHELON-2 trial evaluating Adcetris (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).

The positive topline results of the phase III ECHELON-2 clinical trial were announced in October 2018 and full data will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting, December 1-4, 2018 in San Diego, Calif. Adcetris is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of PTCL. Adcetris is currently not approved for the frontline treatment of PTCL.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.